Danazol
- Generic Name
- Danazol
- Brand Names
- Cyclomen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27NO2
- CAS Number
- 17230-88-5
- Unique Ingredient Identifier
- N29QWW3BUO
- Background
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
- Indication
For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
- Associated Conditions
- Endometriosis, Fibrocystic Disease of Breast, Hereditary Angioedema (HAE), Refractory immune thrombocytopenia
- Associated Therapies
- -
The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04481282
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 195
- Registration Number
- NCT04173494
- Locations
- 🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Effect of Danazol on Endometrial αvβ3 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 38
- Registration Number
- NCT03563664
- Locations
- 🇪🇬
Ain SHams Maternity Hospital, Cairo, Abbaseya, Egypt
The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03460808
- Locations
- 🇨🇳
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China
Low-Dose Danazol for the Treatment of Telomere Related Diseases
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 40
- Registration Number
- NCT03312400
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 34
- Registration Number
- NCT02002403
Danazol Treatment in Endometriosis Women Before IVF
- Conditions
- Interventions
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2016-04-27
- Target Recruit Count
- 150
- Registration Number
- NCT01779232
- Locations
- 🇮🇹
CERM, Rome, Italy
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 14
- Registration Number
- NCT01732445
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Tisch Cancer Center, New York, New York, United States
The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT01667263
- Locations
- 🇨🇳
Beijing Hospital, Ministry of Health, Beijing, Beijing, China
🇨🇳Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Peking University Insititute of Hematology, Beijing, Beijing, China
Danazol for Genetic Bone Marrow and Lung Disorders
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2018-08-15
- Target Recruit Count
- 27
- Registration Number
- NCT01441037
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.